跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

89434

Supelco

头孢曲松 二钠盐 半(七水合物)

analytical standard

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C18H16N8Na2O7S3 · 3.5H2O
CAS号:
104376-79-6
分子量:
661.60
EC號碼:
277-930-0
MDL號碼:
MFCD01750405
分類程式碼代碼:
41116107
PubChem物質ID:
329769734
NACRES:
NA.24

等級

analytical standard

品質等級

100

化驗

≥90% (HPLC)

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

雜質

~10% water

應用

clinical testing

格式

neat

儲存溫度

2-8°C

SMILES 字串

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChI 密鑰

PMRZKYOXTPBIQF-MAODNAKNSA-J

正在寻找类似产品? 访问 产品对比指南

一般說明

Chemical structure: ß-lactam

應用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險分類

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
BCCB9995
BCBW9871
BCBV1668
BCBT9990
BCBT0381

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anthony R Flores et al.
The Journal of infectious diseases, 209(10), 1520-1523 (2013-12-07)
Invasive group A streptococcal (GAS) strains often have genetic differences compared to GAS strains from nonsterile sites. Invasive, "hypervirulent" GAS strains can arise from a noninvasive progenitor following subcutaneous inoculation in mice, but such emergence has been rarely characterized in
Ning Li et al.
Pediatrics, 133(4), e917-e922 (2014-03-26)
Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children. We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history
Emphysematous pyelitis.
Kendall Luyt et al.
The Journal of pediatrics, 166(1), 201-201 (2014-10-01)
Bo Du et al.
Brain injury, 28(11), 1413-1416 (2014-05-17)
Intraventricular fibrinolysis (IVF) through bilateral external ventricular drains (EVD) may provide better access of the thrombolytic agent to the intraventricular clot, potentially leading to faster clot clearance. To compare the feasibility and safety between single and bilateral EVD groups. Patients
Michael S Northrop et al.
Journal of pediatric hematology/oncology, 37(1), e63-e66 (2014-06-01)
Ceftriaxone is a frequently used empiric antibiotic in children. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with a high mortality rate. A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone.
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门